ImmuneSpec is a company headquartered in Belgium.
ImmuneSpec provides immunopeptidomics (MHC-associated peptide proteomics, MAPPs) laboratory services to identify presented peptides for immunogenicity risk assessment, target discovery (including neoantigen discovery) and construct validation. Their services support biotherapeutic development, vaccine design and immuno-oncology research.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.